GW Pharmaceuticals Gets Positive Result for Cannabis-based Epilepsy Drug
15 March 2016 - 12:20AM
Dow Jones News
LONDON—GW Pharmaceuticals PLC said its cannabis-derived drug for
children with severe epilepsy significantly reduced the number of
seizures they suffered in a phase-three trial, paving the way for
the first-ever U.S. approval of a drug of its kind. Shares in the
company climbed more than 130% on the news.
The drug, called Epidiolex, reduced the frequency of seizures by
39% in children with a severe form of epilepsy known as Dravet
syndrome who took the drug on top of their existing drug regime
over a treatment period of 14 weeks. That compared with a 13%
reduction in those who took a placebo on top of their existing drug
combination.
GW said it planned to use the data to file for approval of the
drug with the U.S. Food and Drug Administration, which has already
granted the drug certain priority designations to accelerate its
approval. If approved, it would be the first cannabis-based
medicine to receive the green light from the FDA.
GW Pharma shares â <rose as much as 136% to 512 pence in
London trading, after the 1100 GMT release of the news.
(END) Dow Jones Newswires
March 14, 2016 09:05 ET (13:05 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about GW Pharm. (London Stock Exchange): 0 recent articles
More GW Pharm. News Articles